Managing paediatric Obesity: The Shift to Organ-First Care

Current interventions for paediatric obesity are evolving to address systemic organ dysfunction. While intensive health behaviour and lifestyle changes remain the primary first-line approach, access and sustainability barriers often limit their long-term impact. Recent clinical frameworks now categorise the condition through the lens of organ health, viewing it as a core driver of cardiovascular-kidney-metabolic (CKM) syndrome.

Researchers analysed the efficacy of five approved medications for non-syndromic obesity in adolescents. The data shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and phentermine/topiramate demonstrate the most significant results. Emerging evidence suggests these agents may improve blood pressure and kidney outcomes; however, it is important to note that paediatric-specific data for long-term safety and weight-loss durability remains limited at this stage.

Future Directions in paediatric Obesity Treatment

This shift signals a trajectory toward treating CKM syndrome as a single, integrated unit. The focus is moving toward managing metabolic markers early to address organ-related sequelae across the lifespan. Expected downstream developments include:

• Increased emphasis on integrated CKM monitoring to identify early signs of organ dysfunction.
• Improved management of adolescent hypertension and kidney outcomes through the use of adjunctive pharmacotherapy.
• The development of sustained, coordinated care models that bridge the gap between paediatric and adult medicine.

This approach aims to protect the heart and kidneys during vital developmental years, ensuring a more resilient health trajectory from childhood into adulthood.